BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 25461996)

  • 21. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
    Nabhan C; Dyer MJ; Rosen ST
    Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect
    Flowers CR; Nabhan C; Kay NE; Mato A; Lamanna N; Farber CM; Davids MS; Kiselev P; Swern AS; Sullivan K; Flick ED; Sharman JP
    Leuk Lymphoma; 2018 Oct; 59(10):2327-2335. PubMed ID: 29415595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
    Molica S; Giannarelli D; Mirabelli R; Levato L; Gentile M; Lentini M; Morabito F
    Expert Rev Hematol; 2014 Oct; 7(5):691-5. PubMed ID: 25174547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Lin TS
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical presentation, progression, and outcome of patients with clonal B-cell counts of less than 5 × 10(9)/l, 5 to 10 × 10(9)/l, and more than 10 × 10(9)/l and chronic lymphocytic leukemia immunophenotype.
    Foster AE; Nguyen TT; Al-Hammadi N; Frater JL; Hassan A; Kreisel F
    Am J Clin Pathol; 2015 Jan; 143(1):70-7. PubMed ID: 25511144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the optimal initial treatment for chronic lymphocytic leukemia?
    Lin TS
    Oncology (Williston Park); 2007 Dec; 21(14):1641-9; discussion 1649-54, 1659, 1662. PubMed ID: 18247015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New oral small molecules in the treatment of chronic lymphocytic leukemia.
    Lamanna N
    Cancer; 2015 Jun; 121(12):1917-26. PubMed ID: 25690403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
    Byrd JC; Lin TS; Grever MR
    Semin Oncol; 2006 Apr; 33(2):210-9. PubMed ID: 16616068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving treatment for patients with chronic lymphocytic leukemia.
    Shanafelt TD
    Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Lymphocytic Leukemia: Current Concepts.
    Yu EM; Kittai A; Tabbara IA
    Anticancer Res; 2015 Oct; 35(10):5149-65. PubMed ID: 26408673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach.
    O'Brien SM; Furman RR; Byrd JC; Smith A
    Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 3):1-13. PubMed ID: 24870382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
    Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future directions of clinical trials in chronic lymphocytic leukemia.
    Nerenstone SR; Archer JI; Cheson BD
    Oncology (Williston Park); 1987 Oct; 1(8):31-40, 44. PubMed ID: 3079490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
    Robak T; Kasznicki M
    Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment.
    Condoluci A; Rossi D
    Expert Rev Hematol; 2019 Feb; 12(2):89-98. PubMed ID: 30686074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic lymphocytic leukemia: diagnosis and treatment.
    Yee KW; O'Brien SM
    Mayo Clin Proc; 2006 Aug; 81(8):1105-29. PubMed ID: 16901035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.
    Velez NF; Karia PS; Vartanov AR; Davids MS; Brown JR; Schmults CD
    JAMA Dermatol; 2014 Mar; 150(3):280-7. PubMed ID: 24429548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on signal inhibitors in chronic lymphocytic leukemia.
    Boddu P; Jain N
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemiologic, clinical and therapeutic aspects of chronic lymphoid leukemia: apropos of 120 cases].
    Khalifa M; Chehata S; Laatiri MA; Grira C; Gharbi O; Kortas M; Khelif A; Ennabli S
    Tunis Med; 2002 Oct; 80(10):584-9. PubMed ID: 12632751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.